Welcome to our dedicated page for Regeneron Pharmaceuticals SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a publicly traded biotechnology company incorporated in New York, Regeneron files a range of documents that detail its financial performance, risk factors, material events and governance.
Among the most frequently referenced filings are current reports on Form 8‑K, which Regeneron uses to furnish press releases announcing quarterly and annual financial and operating results. For example, the company has filed Forms 8‑K to report results for quarters ended June 30, 2025 and September 30, 2025, and to describe specific items such as acquired in‑process research and development charges related to collaboration agreements. These filings help investors understand how licensing deals, development milestones and other events affect reported earnings.
In addition to 8‑K reports, investors typically review annual reports on Form 10‑K and quarterly reports on Form 10‑Q for a comprehensive view of Regeneron’s business. These documents generally include information on its portfolio of medicines and product candidates, collaboration structures with partners such as Sanofi, Bayer, Alnylam and Tessera Therapeutics, and descriptions of proprietary platforms like VelocImmune and VelociSuite. They also outline key risks related to clinical development, regulatory approvals, manufacturing, competition and reimbursement.
Stock Titan enhances access to Regeneron’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. AI-generated overviews can help explain complex sections of lengthy 10‑K and 10‑Q reports, highlight notable items in 8‑K disclosures and clarify technical language around non‑GAAP financial measures or collaboration accounting. Users can also review insider transaction reports on Form 4, proxy statements on Schedule 14A and other documents relevant to governance and executive compensation.
By using this page, investors, analysts and researchers can quickly locate and interpret Regeneron’s official SEC filings, while AI tools assist in identifying the portions most relevant to financial performance, pipeline progress and material corporate events.